

G. Y. S. K. Swamy* and
K. RavikumarLaboratory of X-ray Crystallography, Indian
Institute of Chemical Technology, Hyderabad
500 007, India

Correspondence e-mail: swamy@iictnet.org

Key indicators


Single-crystal X-ray study
 $T = 273$ K
Mean $\sigma(\text{C}-\text{C}) = 0.002$ Å
 R factor = 0.033
 wR factor = 0.090
Data-to-parameter ratio = 13.4For details of how these key indicators were
automatically derived from the article, see
<http://journals.iucr.org/e>.2-(Methylsulfanyl)-1*H*-benzimidazole

The benzimidazole ring system in the title molecule, $\text{C}_8\text{H}_8\text{N}_2\text{S}$, is planar. The imidazole ring does not exhibit a delocalized aromatic bond system. Molecules are linked by $\text{N}-\text{H}\cdots\text{N}$ hydrogen bonds along the c axis. The crystal structure is further stabilized by $\text{C}-\text{H}\cdots\pi$ interactions.

Received 21 October 2005
Accepted 15 November 2005
Online 23 November 2005

Comment

2-Mercaptobenzimidazole (MBI), a widely used antioxidant for rubbers and plastics, has a potent thyrotoxic effect in rats (Kawasaki *et al.*, 1998). Human exposure to MBI occurs through the use of rubber products processed with this antioxidant for vulcanization (Airaud *et al.*, 1990). MBI is rather stable and might act as an environmental endocrine disrupter. Methylated derivatives of MBI for industrial supply are much less toxic (Paynter *et al.*, 1988). Further, they are known to be efficient corrosion inhibitors for metals and alloys in various aggressive media (Donnelly *et al.*, 1978). Keeping in view the importance of such compounds, we report here the crystal structure of the title compound, (I).



The fused ring system in (I) is planar with a maximum deviation of 0.011 (1) Å for the atom C3; atoms S1 and C8 are also coplanar with it. The geometrical parameters of the imidazole ring system are consistent with those in the literature (Ravishankar *et al.*, 2005). In the imidazole ring, there is significant shortening of the $\text{N1}-\text{C3}$ bond and lengthening of the $\text{N1}-\text{C4}$ bond (Table 1) compared with the values for




Figure 1
A view of (I) with the atom-numbering scheme. Displacement ellipsoids are drawn at the 30% probability level.




Figure 2
A packing diagram of (I), showing the N—H...N interactions along the *c* axis. H atoms not involved in hydrogen bonding have been omitted for clarity.

2-mercaptobenzimidazole (Form *et al.*, 1976); this indicates a failure to form the delocalized aromatic system which might be expected for this molecule. The C3—S1 and C8—S1 bond lengths [1.7374 (16) and 1.783 (2) Å] possess 36% and 19% SCF- π bond character, respectively (Trinajstić, 1968). The methyl substituent at atom S1 has an impact on the bond lengths and angles of the five-membered heterocycle. This can be seen clearly by comparing S1—C3—N2 and S1—C3—N1 (Table 1) with the corresponding angles in structures with no substitution at the S atom (Kitano *et al.*, 1991; Ravikumar *et al.*, 1995).

The molecules are linked by N—H...N hydrogen bonds, forming chains along the *c* axis (Fig. 2). The structure is further stabilized by a C—H... π interaction involving the methyl H8A atom and the nine-membered benzimidazole ring system (Table 2).

Experimental

The title compound was obtained from Sigma–Aldrich and recrystallized from methanol.

Crystal data

C₈H₈N₂S
M_r = 164.22
 Monoclinic, *P*2₁/*c*
a = 6.9279 (4) Å
b = 11.4613 (7) Å
c = 10.1980 (7) Å
 β = 99.052 (1)°
V = 799.66 (9) Å³
Z = 4

D_x = 1.364 Mg m⁻³
 Mo *K* α radiation
 Cell parameters from 2320 reflections
 θ = 2.7–27.8°
 μ = 0.33 mm⁻¹
T = 273 (2) K
 Block, colourless
 0.22 × 0.18 × 0.16 mm

Data collection

Bruker Smart APEX CCD area-detector diffractometer
 ω scans
 Absorption correction: none
 7479 measured reflections
 1405 independent reflections

1298 reflections with *I* > 2 σ (*I*)
*R*_{int} = 0.021
 θ _{max} = 25.0°
h = -8 → 8
k = -13 → 13
l = -12 → 12

Refinement

Refinement on *F*²
R[*F*² > 2 σ (*F*²)] = 0.033
 ωR (*F*²) = 0.090
S = 1.03
 1405 reflections
 105 parameters
 H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.0499P)^2 + 0.2519P]$
 where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\max} < 0.001$
 $\Delta\rho_{\max} = 0.22 \text{ e } \text{Å}^{-3}$
 $\Delta\rho_{\min} = -0.20 \text{ e } \text{Å}^{-3}$

Table 1

Selected geometric parameters (Å, °).

C2—N2	1.378 (2)	C3—N2	1.3584 (19)
C3—N1	1.3160 (19)	C4—N1	1.3931 (19)
N1—C3—S1	126.90 (11)	N2—C3—S1	119.56 (11)
C1—C2—C4—N1	178.88 (14)	N2—C3—S1—C8	176.47 (13)
S1—C3—N2—C2	176.79 (10)		

Table 2

Hydrogen-bond geometry (Å, °).

<i>D</i> —H... <i>A</i>	<i>D</i> —H	H... <i>A</i>	<i>D</i> ... <i>A</i>	<i>D</i> —H... <i>A</i>
N2—H2N...N1 ⁱ	0.84 (2)	2.07 (2)	2.8769 (17)	160 (2)
C8—H8A...Cg1 ⁱⁱ	0.96	2.71	3.58	150

Symmetry codes: (i) *x*, -*y* + $\frac{3}{2}$, *z* - $\frac{1}{2}$; (ii) -*x* + 2, *y* + $\frac{1}{2}$, -*z* + $\frac{1}{2}$. Cg1 is the centroid of the benzimidazole ring system.

The H atom attached to the N atom was located in a difference density map and refined freely. All other H atoms were placed in geometrically idealized positions and allowed to ride with C—H distances in the range 0.93–0.97 Å, and with *U*_{iso}(H) = 1.2–1.5 *U*_{eq}(C)...

Data collection: *SMART* (Bruker, 2001); cell refinement: *SAINT* (Bruker, 2001); data reduction: *SAINT*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEP3* (Farrugia, 1997) and *PLATON* (Spek, 2003); software used to prepare material for publication: *SHELXL97* and *PARST* (Nardelli, 1995).

The authors thank Dr J. S. Yadav, Director, IICT, Hyderabad, for his kind encouragement.

References

- Airaudo, C. B., Gayte-Sorbier, A., Momburg, R. & Laurent, P. (1990). *J. Biomater. Sci. Polym. Ed.* **1**, 231–241.
 Bruker (2001). *SAINT* (Version 6.28a) and *SMART* (Version 5.625). Bruker AXS Inc., Madison, Wisconsin, USA.
 Donnelly, B., Downie, T. C., Grzeskowiak, R., Hamburg, H. R. & Short, D. (1978). *Corros. Sci.* **18**, 109–116.
 Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
 Form, G. R., Raper, E. S. & Downie, T. C. (1976). *Acta Cryst.* **B32**, 345–348.

- Kawasaki, Y., Umemura, T., Saito, M., Momma, J., Matsushima, Y., Sekiguchi, H., Matsumoto, M., Sakemi, K., Isama, K., Inoue, T., Kurokawa, Y. & Tsuda, M. (1998). *J. Toxicol. Sci.* **23**, 53–68.
- Kitano, Y., Ishitani, A., Sato, H., Imamura, S. & Ashida, T. (1991). *Acta Cryst. C* **47**, 1269–1271.
- Nardelli, M. (1995). *J. Appl. Cryst.* **28**, 659.
- Paynter, O. E., Burin, G. J., Jaeger, R. B. & Gregorio, C. A. (1988). *Regul. Toxicol. Pharmacol.* **8**, 102–119.
- Ravikumar, K., Chandra Mohan, K., Bidasagar, M. & Swamy, G. Y. S. K. (1995). *J. Chem. Crystallogr.* **25**, 325–329.
- Ravishankar, T., Chinnakali, K., Arumugam, N., Srinivasan, P. C., Usman, A. & Fun, H.-K. (2005). *Acta Cryst. E* **61**, o1184–o1186.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Gottingen, Germany.
- Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.
- Trinajstić, N. (1968). *Tetrahedron Lett.* **9**, 1529–1532.